{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T18:59:22Z","timestamp":1785265162315,"version":"3.55.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T00:00:00Z","timestamp":1674000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05242-w","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T03:34:12Z","timestamp":1674012852000},"page":"1297-1306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Renal involvement in Sj\u0151gren\u2019s syndrome: predictors and impact on patient outcomes"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-0178","authenticated-orcid":false,"given":"Rudrarpan","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4021-0654","authenticated-orcid":false,"given":"Anu","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-2198","authenticated-orcid":false,"given":"Rajat","family":"Kharbanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1658-8155","authenticated-orcid":false,"given":"Upendra","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2753-2990","authenticated-orcid":false,"given":"Latika","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5035-7396","authenticated-orcid":false,"given":"Durga P.","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-1233","authenticated-orcid":false,"given":"Vikas","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-5186","authenticated-orcid":false,"given":"Amita","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3439-8048","authenticated-orcid":false,"given":"Able","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"issue":"2","key":"5242_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","volume":"53","author":"M Ramos-Casals","year":"2014","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Solans R, Camps M-T, Casanovas A, Sope\u00f1a B et al (2014) Systemic involvement in primary Sjogren\u2019s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS registry). Rheumatol Oxf Engl 53(2):321\u2013331","journal-title":"Rheumatol Oxf Engl"},{"key":"5242_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2174\/1874312901409010036","volume":"9","author":"P Sandhya","year":"2009","unstructured":"Sandhya P, Jeyaseelan L, Scofield RH, Danda D (2009) Clinical characteristics and outcome of primary Sjogren\u2019s syndrome: a large asian indian cohort. Open Rheumatol J 9:36\u201345","journal-title":"Open Rheumatol J"},{"issue":"12","key":"5242_CR3","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00296-018-4118-x","volume":"38","author":"A Jain","year":"2018","unstructured":"Jain A, Srinivas BH, Emmanuel D, Jain VK, Parameshwaran S, Negi VS (2018) Renal involvement in primary Sjogren\u2019s syndrome: a prospective cohort study. Rheumatol Int 38(12):2251\u20132262","journal-title":"Rheumatol Int"},{"issue":"5","key":"5242_CR4","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0049-0172(00)80016-5","volume":"29","author":"FN Skopouli","year":"2000","unstructured":"Skopouli FN, Dafni U, Ioannidis JP, Moutsopoulos HM (2000) Clinical evolution, and morbidity and mortality of primary Sj\u00f6gren\u2019s syndrome. Semin Arthritis Rheum 29(5):296\u2013304","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"5242_CR5","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1002\/art.38100","volume":"65","author":"AV Goules","year":"2013","unstructured":"Goules AV, Tatouli IP, Moutsopoulos HM, Tzioufas AG (2013) Clinically significant renal involvement in primary Sj\u00f6gren\u2019s syndrome: clinical presentation and outcome: clinical presentation and outcome of significant renal involvement in SS. Arthritis Rheum 65(11):2945\u20132953","journal-title":"Arthritis Rheum"},{"key":"5242_CR6","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nrrheum.2013.110","volume":"9","author":"G Nocturne","year":"2013","unstructured":"Nocturne G, Mariette X (2013) Advances in understanding the pathogenesis of primary Sj\u00f6gren\u2019s syndrome. Nat Rev Rheumatol 9:544\u2013556","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"5242_CR7","first-page":"362","volume":"56","author":"M Jasiek","year":"2017","unstructured":"Jasiek M, Karras A, Le Guern V, Krastinova E, Mesbah R, Faguer S et al (2017) A multicentre study of 95 biopsy-proven cases of renal disease in primary Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford) 56(3):362\u2013370","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"5242_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1053\/j.ajkd.2008.07.025","volume":"52","author":"YK Kim","year":"2008","unstructured":"Kim YK, Song HC, Kim WY, Yoon HE, Choi YJ, Ki CS et al (2008) Acquired Gitelman syndrome in a patient with primary Sj\u00f6gren syndrome. Am J Kidney Dis 52(6):1163\u20131167","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"5242_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/nrneph.2015.174","volume":"12","author":"H Fran\u00e7ois","year":"2016","unstructured":"Fran\u00e7ois H, Mariette X (2016) Renal involvement in primary Sj\u00f6gren syndrome. Nat Rev Nephrol 12(2):82\u201393","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"5242_CR10","first-page":"123","volume":"118","author":"AV Goules","year":"2019","unstructured":"Goules AV, Geetha D, Arend LJ, Baer AN (2019) Renal involvement in primary Sj\u00f6gren\u2019s syndrome: natural history and treatment outcome. Clin Exp Rheumatol 118(3):123\u2013132","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"5242_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/1756-185X.13182","volume":"21","author":"HX Yang","year":"2018","unstructured":"Yang HX, Wang J, Wen YB, Fei YY, Jiang MD, Zhou MY et al (2018) Renal involvement in primary Sj\u00f6gren\u2019s syndrome: a retrospective study of 103 biopsy-proven cases from a single center in China. Int J Rheum Dis 21(1):223\u2013229","journal-title":"Int J Rheum Dis"},{"issue":"10159","key":"5242_CR12","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators (2018) Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet 392(10159):1789\u20131858","journal-title":"Lancet"},{"issue":"1","key":"5242_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.39859","volume":"69","author":"CH Shiboski","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM et al (2017) 2016 American college of rheumatology\/european league against rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 69(1):35\u201345","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"5242_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/00005792-200007000-00005","volume":"79","author":"A Goules","year":"2000","unstructured":"Goules A, Masouridi S, Tzioufas AG, Ioannidis JP, Skopouli FN, Moutsopoulos HM (2000) Clinically significant and biopsy-documented renal involvement in primary Sj\u00f6gren syndrome. Medicine 79(4):241\u2013249","journal-title":"Medicine"},{"issue":"1","key":"5242_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, M\u00e4chler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67(1):1\u201348","journal-title":"J Stat Softw"},{"issue":"13","key":"5242_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v082.i13","volume":"82","author":"A Kuznetsova","year":"2017","unstructured":"Kuznetsova A, Brockhoff PB, Christensen RHB (2017) lmer test package: tests in linear mixed effects models. J Stat Softw 82(13):1\u201326","journal-title":"J Stat Softw"},{"issue":"2","key":"5242_CR17","first-page":"278","volume":"35","author":"H Ren","year":"2008","unstructured":"Ren H, Wang W-M, Chen X-N, Zhang W, Pan X-X, Wang X-L et al (2008) Renal involvement and followup of 130 patients with primary Sj\u00f6gren\u2019s syndrome. J Rheumatol 35(2):278\u2013284","journal-title":"J Rheumatol"},{"key":"5242_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3952392","volume":"2019","author":"J Luo","year":"2019","unstructured":"Luo J, Huo Y-W, Wang J-W, Guo H (2019) High-risk indicators of renal involvement in primary Sjogren\u2019s syndrome: a clinical study of 1002 cases. J Immunol Res 2019:e3952392","journal-title":"J Immunol Res"},{"key":"5242_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.594096","volume":"11","author":"AV Goules","year":"2020","unstructured":"Goules AV, Argyropoulou OD, Pezoulas VC, Chatzis L, Critselis E, Gandolfo S et al (2020) Primary Sj\u00f6gren\u2019s syndrome of early and late onset: distinct clinical phenotypes and lymphoma development. Front Immunol 11:594096","journal-title":"Front Immunol"},{"issue":"3","key":"5242_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1191\/096120398678920019","volume":"7","author":"M Ramos-Casals","year":"1998","unstructured":"Ramos-Casals M, Cervera R, Font J, Garc\u00eda-Carrasco M, Espinosa G, Reino S et al (1998) Young onset of primary Sj\u00f6gren\u2019s syndrome: clinical and immunological characteristics. Lupus 7(3):202\u2013206","journal-title":"Lupus"},{"issue":"7","key":"5242_CR21","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/rheumatology\/key392","volume":"58","author":"C Anquetil","year":"2019","unstructured":"Anquetil C, Hachulla E, Machuron F, Mariette X, Le Guern V, Vittecoq O et al (2019) Is early-onset primary Sj\u00f6gren\u2019s syndrome a worse prognosis form of the disease? Rheumatology (Oxford) 58(7):1163\u20131167","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"5242_CR22","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2215\/CJN.00980209","volume":"4","author":"S Maripuri","year":"2009","unstructured":"Maripuri S, Grande JP, Osborn TG, Fervenza FC, Matteson EL, Donadio JV et al (2009) Renal involvement in primary Sj\u00f6gren\u2019s syndrome: a clinicopathologic study. Clin J Am Soc Nephrol CJASN 4(9):1423\u20131431","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"5","key":"5242_CR23","doi-asserted-by":"publisher","first-page":"e59868","DOI":"10.1371\/journal.pone.0059868","volume":"8","author":"J-E Gottenberg","year":"2013","unstructured":"Gottenberg J-E, Seror R, Miceli-Richard C, Benessiano J, Devauchelle-Pensec V, Dieude P et al (2013) Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sj\u00f6gren\u2019s syndrome data at enrollment in the prospective ASSESS cohort. PLoS ONE 8(5):e59868","journal-title":"PLoS ONE"},{"issue":"5","key":"5242_CR24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/rheumatology\/ket427","volume":"53","author":"C Baldini","year":"2014","unstructured":"Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A et al (2014) Primary Sjogren\u2019s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients. Rheumatol Oxf Engl 53(5):839\u2013844","journal-title":"Rheumatol Oxf Engl"},{"issue":"4","key":"5242_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/MD.0b013e318181e6af","volume":"87","author":"M Ramos-Casals","year":"2008","unstructured":"Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, Del Pino-Montes J et al (2008) Primary Sj\u00f6gren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 87(4):210\u2013219","journal-title":"Medicine (Baltimore)"},{"issue":"22","key":"5242_CR26","first-page":"3252","volume":"123","author":"D-F Lin","year":"2010","unstructured":"Lin D-F, Yan S-M, Zhao Y, Zhang W, Li M-T, Zeng X-F et al (2010) Clinical and prognostic characteristics of 573 cases of primary Sj\u00f6gren\u2019s syndrome. Chin Med J (Engl) 123(22):3252\u20133257","journal-title":"Chin Med J (Engl)"},{"key":"5242_CR27","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fimmu.2019.00312","volume":"10","author":"I Bodewes","year":"2019","unstructured":"Bodewes I, van der Spek PJ, Leon LG, Wijkhuijs A, van Helden-Meeuwsen CG, Tas L et al (2019) Fatigue in Sj\u00f6gren\u2019s syndrome: a search for biomarkers and treatment targets. Front Immunol 10:312","journal-title":"Front Immunol"},{"issue":"6","key":"5242_CR28","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1177\/0961203321995246","volume":"30","author":"S Majumder","year":"2021","unstructured":"Majumder S, Singh P, Chatterjee R, Pattnaik SS, Aggarwal A (2021) Elevated urinary IL-36\u03b3 in patients with active lupus nephritis and response to treatment. Lupus 30(6):921\u2013925","journal-title":"Lupus"},{"issue":"3","key":"5242_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001832","volume":"7","author":"KB Norheim","year":"2021","unstructured":"Norheim KB, Imgenberg-Kreuz J, Alexsson A, Johnsen SJA, B\u00e5rdsen K, Brun JG et al (2021) Genetic variants at the RTP4\/MASP1 locus are associated with fatigue in scandinavian patients with primary Sj\u00f6gren\u2019s syndrome. RMD Open 7(3):e001832","journal-title":"RMD Open"},{"issue":"5","key":"5242_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.chom.2020.09.014","volume":"28","author":"IN Boys","year":"2020","unstructured":"Boys IN, Xu E, Mar KB, De La Cruz-Rivera PC, Eitson JL, Moon B, Schoggins JW (2020) RTP4 is a potent IFN-inducible anti-flavivirus effector engaged in a host-virus arms race in bats and other mammals. Cell Host Microbe 28(5):712-723.e9","journal-title":"Cell Host Microbe"},{"issue":"2","key":"5242_CR31","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","volume":"1","author":"JR Tarn","year":"2019","unstructured":"Tarn JR, Howard-Tripp N, Lendrem DW, Mariette X, Saraux A, Devauchelle-Pensec V et al (2019) Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol 1(2):e85-94","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"5242_CR32","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.semarthrit.2020.07.013","volume":"50","author":"OD Argyropoulou","year":"2020","unstructured":"Argyropoulou OD, Pezoulas V, Chatzis L, Critselis E, Gandolfo S, Ferro F et al (2020) Cryoglobulinemic vasculitis in primary Sj\u00f6gren\u2019s syndrome: clinical presentation, association with lymphoma and comparison with hepatitis C-related disease. Semin Arthritis Rheum 50(5):846\u2013853","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"5242_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","volume":"75","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n P, Kostov B, Solans R, Fraile G, Su\u00e1rez-Cuervo C, Casanovas A et al (2016) Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS disease activity index (ESSDAI) in 1045 patients. Ann Rheum Dis 75(2):348\u2013355","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5242_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/MD.0b013e3181b76ab5","volume":"88","author":"E Baimpa","year":"2009","unstructured":"Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM (2009) Hematologic manifestations and predictors of lymphoma development in primary Sj\u00f6gren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore) 88(5):284\u2013293","journal-title":"Medicine (Baltimore)"},{"key":"5242_CR35","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jaut.2013.10.002","volume":"51","author":"L Quartuccio","year":"2014","unstructured":"Quartuccio L, Isola M, Baldini C, Priori R, Bartoloni Bocci E, Carubbi F et al (2014) Biomarkers of lymphoma in Sj\u00f6gren\u2019s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J Autoimmun 51:75\u201380","journal-title":"J Autoimmun"},{"issue":"4","key":"5242_CR36","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/ni.2548","volume":"14","author":"WA McEwan","year":"2013","unstructured":"McEwan WA, Tam JCH, Watkinson RE, Bidgood SR, Mallery DL, James LC (2013) Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol 14(4):327\u2013336","journal-title":"Nat Immunol"},{"issue":"3","key":"5242_CR37","first-page":"1780","volume":"181","author":"R Higgs","year":"2008","unstructured":"Higgs R, Gabhann JN, Larbi NB, Breen EP, Fitzgerald KA, Jefferies CA (2008) The E3 ubiquitin ligase Ro52 negatively regulates IFN-\u03b2 production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol Baltim Md 1950 181(3):1780\u20131786","journal-title":"J Immunol Baltim Md 1950"},{"issue":"8","key":"5242_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0103609","volume":"9","author":"E Lazzari","year":"2014","unstructured":"Lazzari E, Korczeniewska J, N\u00ed Gabhann J, Smith S, Barnes BJ, Jefferies CA (2014) TRIpartite motif 21 (TRIM21) differentially regulates the stability of interferon regulatory factor 5 (IRF5) isoforms. PLoS ONE 9(8):e103609","journal-title":"PLoS ONE"},{"issue":"7","key":"5242_CR39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011776","volume":"5","author":"R Higgs","year":"2010","unstructured":"Higgs R, Lazzari E, Wynne C, N\u00ed Gabhann J, Espinosa A, Wahren-Herlenius M et al (2010) Self protection from anti-viral responses\u2013Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS ONE 5(7):e11776","journal-title":"PLoS ONE"},{"issue":"9","key":"5242_CR40","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/rheumatology\/kev223","volume":"54","author":"R Evans","year":"2015","unstructured":"Evans R, Zdebik A, Ciurtin C, Walsh SB (2015) Renal involvement in primary Sj\u00f6gren\u2019s syndrome. Rheumatology 54(9):1541\u20131548","journal-title":"Rheumatology"},{"issue":"1","key":"5242_CR41","first-page":"10","volume":"56","author":"M Pertovaara","year":"2001","unstructured":"Pertovaara M, Korpela M, Pasternack A (2001) Factors predictive of renal involvement in patients with primary Sj\u00f6gren\u2019s syndrome. Clin Nephrol 56(1):10\u201318","journal-title":"Clin Nephrol"},{"issue":"2","key":"5242_CR42","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/1756-185X.13429","volume":"22","author":"J Luo","year":"2019","unstructured":"Luo J, Xu S, Lv Y, Huang X, Zhang H, Zhu X et al (2019) Clinical features and potential relevant factors of renal involvement in primary Sj\u00f6gren\u2019s syndrome. Int J Rheum Dis 22(2):182\u2013190","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"5242_CR43","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","volume":"72","author":"J-E Gottenberg","year":"2013","unstructured":"Gottenberg J-E, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O et al (2013) Efficacy of rituximab in systemic manifestations of primary Sjogren\u2019s syndrome: results in 78 patients of the autoimmune and rituximab registry. Ann Rheum Dis 72(6):1026\u20131031","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"5242_CR44","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1159\/000484903","volume":"46","author":"Y Shen","year":"2017","unstructured":"Shen Y, Xie J, Lin L, Li X, Shen P, Pan X, Ren H, Chen N (2017) Combination cyclophosphamide\/glucocorticoids provide better tolerability and outcomes versus glucocorticoids alone in patients with Sjogren\u2019s associated chronic interstitial nephritis. Am J Nephrol 46(6):473\u2013480","journal-title":"Am J Nephrol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05242-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05242-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05242-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T15:10:58Z","timestamp":1684163458000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05242-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,18]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["5242"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05242-w","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,18]]},"assertion":[{"value":"27 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rudrarpan Chatterjee, Anu Balakrishnan, Rajat Kharbanda, Upendra Rathore, Latika Gupta, Durga P Misra, Vikas Agarwal, Amita Aggarwal and Able Lawrence declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}